Enanta Pharmaceuticals
ENTA
176 hedge funds and large institutions have $1.08B invested in Enanta Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 81 increasing their positions, 54 reducing their positions, and 31 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 54
1.19% more ownership
Funds ownership: 89.73% → 90.92% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 194 → 176 (-18)
28% less call options, than puts
Call options by funds: $5.22M | Put options by funds: $7.2M
28% less capital invested
Capital invested by funds: $1.49B → $1.08B (-$414M)
58% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$23.3M |
| 2 |
AC
Armistice Capital
New York
|
+$14.9M |
| 3 |
Man Group
London,
United Kingdom
|
+$14.2M |
| 4 |
Renaissance Technologies
New York
|
+$8.36M |
| 5 |
Goldman Sachs
New York
|
+$7.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$34.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$13M |
| 3 |
First Manhattan
New York
|
-$8.11M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$5.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.47M |
ENTA Hedge Fund Activity: Q3 2019 in Review
176 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2019, worth a combined $1.08B — down 28% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ENTA and 13 opened new positions — a net loss of 18 holders — while 54 trimmed existing stakes and 81 added.
The largest buyer was Farallon Capital Management, adding an estimated $23.3M. The largest seller was Ameriprise, cutting an estimated $34.9M.
- 176 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2019, down from 194 in Q2 2019.
- Funds reported $1.08B of Enanta Pharmaceuticals stock for Q3 2019, down 28% quarter-over-quarter.
- 13 funds opened new Enanta Pharmaceuticals positions in Q3 2019 and 31 closed out, a net change of -18 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2019 was Farallon Capital Management, an estimated $23.3M added.
- The largest Enanta Pharmaceuticals seller in Q3 2019 was Ameriprise, an estimated $34.9M sold.
Based on aggregated 13F filings for Q3 2019.